GlassScript(Dd1) Duo Hybrid
Payments companies reported to CMS as associated with (Dd1) Duo Hybrid. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with (Dd1) Duo Hybrid, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with (Dd1) Duo Hybrid
These are the largest totals companies reported as associated with (Dd1) Duo Hybrid. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Vamsi Krishna | Kyle, TX | Interventional Cardiology | $556.96 |
| Dominic Tolitano | Wood Dale, IL | Thoracic Surgery (Cardiothoracic Vascular Surgery) | $388.36 |
| Marcos Kuroki | Irvine, CA | Vascular Surgery | $254.06 |
| Christopher Skillern | Ventura, CA | Vascular Surgery | $220.28 |
| Andrea Fisher | Palo Alto, CA | Vascular Surgery | $143.84 |
| Keyuree Satam | Stanford, CA | $143.84 | |
| Michael Blanc | San Angelo, TX | Interventional Cardiology | $139.92 |
| Vinay Arora | Westmont, IL | Cardiovascular Disease | $138.37 |
| Kristin Lentz | Minneapolis, MN | Nurse Practitioner | $138.37 |
| Suveer Tatineni | Aurora, IL | Vascular & Interventional Radiology | $138.36 |
Prescribed (Dd1) Duo Hybrid?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.